? San Diego-based Equillium has nabbed an orphan drug designation for EQ001 on the verge of beginning a Phase Ib/II for the immuno-inflammatory drug. Also known as itolizumab, the drug was in-licensed from India?s Biocon, which sells it in the country as a psoriasis treatment. Equillium $EQ, however, is focusing its US clinical work on the prevention and treatment of acute graft-versus-host disease ? a strategy that has allowed it to skip financing rounds and jump str
Related Articles

Lilly, Incyte’s baricitinib wins fast-track status for hard-to-treat lupus; Synthorx hammers out $150M+ IPO
? Rheumatoid arthritis drug Olumiant?? approved for a narrower-than-expected patient population earlier this year to the dismay of its manufacturer Eli?Lilly $LLY and Incyte $INCY which had blockbuster dreams for the drug?? may be worth its weight in g… […]

GSK plans $100M makeover of US manufacturing site; La Jolla Pharma gets a ‘breakthrough’ with late-stage drug
? GSK $GSK announced today that it will be investing $100 million into its facility in Hamilton, MT to expand long-term vaccine manufacturing capabilities. The expansion will boost production capacity of key components of the adjuvant system used in se… […]

Pfizer takes its option in AnTolRx deal; Secura Bio scores access to $145M for cancer drug launches
? Two-and-a-half years after Pfizer stepped up to seed the biotech startup AnTolRx, the pharma giant has stepped in to take their option on an immune tolerance therapy for Type 1 diabetes. Based on the lab work of Francisco Quintana, a professor of neu… […]